Follicular dendritic cell sarcoma is a rare tumor that occurs mainly in lymph nodes. We report a case of follicular dendritic cell sarcoma in a cervical lymph node that was initially diagnosed as a B-cell lymphoma by Tru-Cut biopsy. The correct diagnosis was established by excision biopsy and immunohistochemistry. This tumor is of interest to head and neck surgeons because its recurrence rate is significant and its metastatic potential has been underestimated because of its rarity and the difficulty in making the diagnosis. We discuss the salient clinical and pathologic features of this tumor, as well as its management protocol, and we review the literature.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Adult-Onset Pediatric-Type Follicular Lymphoma of the Parotid Gland.
Cureus
December 2024
Biomedical Sciences, University of Chicago, Chicago, USA.
Pediatric-type follicular lymphoma (PTFL) is an extremely rare B-cell lymphoma that primarily affects children and young adults, typically in individuals under 25 years old, with a median age of 15 years. Here, we report a rare case of PTFL in a 27-year-old adult male who presented with a slow-growing mass near his left ear. Initial CT scans of the neck revealed two oval-shaped, smooth, well-defined, homogeneously enhancing soft tissue density lesions in the superficial lobe of the left parotid gland.
View Article and Find Full Text PDFTertiary lymphoid structures in colorectal cancer - organization and immune cell interactions.
Am J Clin Exp Immunol
December 2024
Department of Surgery, Medical Faculty, Trakia University Stara Zagora, Bulgria.
Tertiary lymphoid structures (TLS), formerly recognized as Crohn's-like structures, serve as crucial biomarkers for evaluating the progression of colorectal cancer (CRC). Understanding their spatial distribution, cellular composition, and interactions within CRC is paramount for comprehending the immune response in the tumor microenvironment (TME). TLS are comprised of a T-cellular compartment and a B-cellular compartment, the latter encompassing follicular dendritic cells (FDCs), high endothelial venules (HEVs), and lymphatic vessels.
View Article and Find Full Text PDFDual targeting PD-L1 and 4-1BB to overcome dendritic cell-mediated lenalidomide resistance in follicular lymphoma.
Signal Transduct Target Ther
January 2025
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Immunomodulatory agent lenalidomide is effective in treating follicular lymphoma (FL). We conducted the first trial of immunotherapy rituximab plus lenalidomide in newly diagnosed FL in China (NCT03715309). One-hundred and fifteen patients were enrolled and treated with rituximab 375 mg/m intravenously on day 0 and lenalidomide 25 mg orally on day 1-10 for 6 cycles of induction treatment, as well as lenalidomide for 6 cycles and rituximab for 8 cycles of maintenance treatment.
View Article and Find Full Text PDFA case report: spleen Epstein-Barr virus-positive inflammatory follicular dendritic cell sarcoma.
J Gastrointest Oncol
December 2024
Department of Radiology, Zhuhai Clinical Medical College of Jinan University (Zhuhai People's Hospital, The Affiliated Hospital of Beijing Institute of Technology), Jinan University, Zhuhai, China.
Background: Epstein-Barr virus-positive (EBV) inflammatory follicular dendritic cell sarcoma (IFDCS) is a rare stroma-derived neoplasm of lymphoid tissues. It typically involves the spleen and liver, and is often associated with the presence of EBV. Because of its nonspecific clinical and imaging findings, making a correct diagnosis at the time of initial diagnosis is challenging.
View Article and Find Full Text PDFALC-0315 Lipid-Based mRNA LNP Induces Stronger Cellular Immune Responses Postvaccination.
Mol Pharm
January 2025
Ningbo No.2 Hospital, Ningbo, Zhejiang 315010, P. R. China.
At the end of 2019, SARS-CoV-2 emerged and rapidly spread, having a profound negative impact on human health and socioeconomic conditions. In response to this unprecedented global health crisis, significant advancements were made in the mRNA vaccine technology. In this study, we have compared the difference between two SARS-CoV-2 receptor-binding domain (RBD) mRNA-Lipid nanoparticle (LNP) vaccines prepared from two different ionizable cationic lipids: ALC-0315 and MC3.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!